Jim Cramer on Pfizer: "We'll Find Out if Pfizer's Going to Be More of a Stock and Less of a Bond Equivalent"

Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented:

“Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with a 7% yield, not much price appreciation. I like growth, but that dividend seems safe, and it’s backed up by cash flow. On Tuesday morning, we’ll find out if Pfizer’s going to be more of a stock and less of a bond equivalent.”

Pfizer Inc. (NYSE:PFE) develops and sells medicines and vaccines across therapeutic areas, including cardiovascular, infectious diseases, immunology, and oncology. A caller inquired about the stock during the October 28 episode and said:

“I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But right now, the drug socks are just in a world of hurt, and this one continues to be there. You can own it. They gotta figure out something. That yield will protect you for a while, though.”

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.